stockrowHarvard Bioscience, Inc. (HBIO) vs Nephros Inc. (NEPH)
- Harvard Bioscience, Inc. HBIO 8.34 −1.42%
- Nephros Inc. NEPH 2.83 −8.41%
Harvard Bioscience, Inc. and Nephros Inc. are both Medical Instruments & Supplies companies. Harvard Bioscience, Inc. is the larger, with a market value of $38.5M against $33.6M — 1.1× the size. Harvard Bioscience, Inc. has negative trailing earnings, so its P/E is not meaningful; Nephros Inc. trades at 18.0×. Nephros Inc. grew revenue faster over the last twelve months: 20.4% against −1.06%. Nephros Inc. has the higher net margin (8.86% vs −11.9%) and the higher return on invested capital (14.3% vs −0.41%). Across the 19 metrics below, Nephros Inc. leads on 15 and Harvard Bioscience, Inc. on 4.
Valuation
Profitability
| Metric | HBIO | NEPH | Medical Instruments & Supplies median |
|---|---|---|---|
| Gross margin | 58.16% | 60.55% | 53.60% |
| Operating margin | (0.28%) | 8.48% | 1.97% |
| Net margin | (11.86%) | 8.86% | 0.00% |
| Free cash flow margin | (2.09%) | (4.22%) | 2.36% |
| Return on equity | (89.95%) | 16.95% | 0.00% |
| Return on assets | (13.32%) | 13.39% | 0.00% |
| Return on invested capital | (0.41%) | 14.29% | 0.13% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack